International cohort studies suggest that adding azithromycin to hydroxychloroquine (HCQ) treatment may increase heart failure and cardiovascular mortality, potentially due to synergistic effects on QT length of ECG. Severe adverse events associated with HCQ-azithromycin were compared to HCQ-amoxicillin in rheumatoid arthritis patients aged 18+ and followed up over 30 days. A total of 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin were included. When azithromycin was added to HCQ, an increased risk of 30-day cardiovascular mortality (HR2.19), chest pain/angina (HR 1.15), and heart failure (HR 1.22) were observed. HCQ is a drug for malarial and for systemic lupus erythematosus. It recently received Emergency Use Authorization by the FDA for use to treat COVID-19 patients. Source: https://www.medrxiv.org/
Higher nighttime light exposure was associated with adverse changes in cardiac structure and function and…
In two UK cohorts including 977,282 adults, drinking beverages at a “very hot” temperature was…
In a UK prospective cohort of 502,188 adults followed for a median of 13.6 years,…
Regular smoking was associated with a lower risk of Parkinson disease (PD), and among people…
Alcohol-attributable cancer deaths in the USA doubled from 11,361 in 1990 to 23,126 in 2023,…
A systematic review and meta-analysis found that the prevalence of unruptured intracranial aneurysms (UIAs) is…
This website uses cookies.